Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Capital Expenditures (2021 - 2025)

Oncology Institute (TOI) has disclosed Capital Expenditures for 5 consecutive years, with $604000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Capital Expenditures rose 250.25% year-over-year to $604000.0, compared with a TTM value of $3.9 million through Sep 2025, up 34.54%, and an annual FY2024 reading of $3.8 million, down 17.04% over the prior year.
  • Capital Expenditures was $604000.0 for Q3 2025 at Oncology Institute, down from $1.2 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $1.8 million in Q1 2023 and bottomed at -$3.5 million in Q4 2022.
  • Average Capital Expenditures over 5 years is $702263.2, with a median of $930000.0 recorded in 2023.
  • The sharpest move saw Capital Expenditures crashed 505.74% in 2022, then surged 250.25% in 2025.
  • Year by year, Capital Expenditures stood at $871000.0 in 2021, then plummeted by 505.74% to -$3.5 million in 2022, then soared by 124.36% to $861000.0 in 2023, then soared by 103.83% to $1.8 million in 2024, then crashed by 65.58% to $604000.0 in 2025.
  • Business Quant data shows Capital Expenditures for TOI at $604000.0 in Q3 2025, $1.2 million in Q2 2025, and $328000.0 in Q1 2025.